While heart disease, diabetes and prediabetes are the most common health concerns related to obesity, many other conditions ...

The holidays can involve a lot of parties and travel, along with the spread of germs and viruses. Here’s how to boost your ...

Eli Lilly and Co (NYSE:LLY) shares are trading higher on Friday. The company plans to start selling its obesity drug through ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of ...

The Indianapolis drug giant's stock (LLY) reached an intraday high of $1,061.17 in morning trading Friday, which was above the threshold of $1,057.78 needed for Lilly to become the 10th U.S. company ...

Serena Williams has endorsed GLP-1 medications, raising questions regarding their stigma and performance-enhancing potential for athletes.

Roughly 1 in 3 adults has metabolic dysfunction–associated steatotic liver disease, or MASLD. A doctor outlines how to detect and slow the condition early.

In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...

Twenty-two years since the series' 2003 premiere, the stylist reflects on his role evolving society toward greater compassion ...